CPRX - Catalyst gets FDA review for higher dose of Firdapse for rare neuromuscular disorder
2023-10-13 09:59:46 ET
More on Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils
- Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing
- Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals
For further details see:
Catalyst gets FDA review for higher dose of Firdapse for rare neuromuscular disorder